Paolo A Ascierto

发表

Discrepant alterations in main candidate genes among multiple primary melanomas

Susanna Rossari, Daniela Massi, Vincenzo De Giorgi, 2014, Journal of Translational Medicine.

Early diagnosis of malignant melanoma: Proposal of a working formulation for the management of cutaneous pigmented lesions from the Melanoma Cooperative Group.

Riccardo Bono, Alessandro Testori, Antonio Daponte, 2003, International journal of oncology.

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.

Paolo A Ascierto, Ariella Sasson, Ryan Golhar, 2018, Cancer cell.

Novel approaches in melanoma prevention and therapy.

Paolo A Ascierto, P. Ascierto, P. Cassidy, 2014, Cancer treatment and research.

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.

Matthew Wongchenko, Paolo A Ascierto, Antoni Ribas, 2016, The Lancet. Oncology.

Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy?

Maria Colombino, Gerardo Botti, Paolo A Ascierto, 2017, Journal of Translational Medicine.

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.

Dirk Schadendorf, Reinhard Dummer, Naoya Yamazaki, 2018, The Lancet. Oncology.

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Dirk Schadendorf, Reinhard Dummer, Paolo A Ascierto, 2015, The New England journal of medicine.

Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types

Paolo A Ascierto, Michael Kalos, P. Ascierto, 2013, Clinical Cancer Research.

MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPIlimumab

Gerardo Botti, Paolo A Ascierto, Gennaro Ciliberto, 2014, Journal of Translational Medicine.

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.

Dirk Schadendorf, Alessandro Testori, Axel Hauschild, 2014, The Lancet. Oncology.

The role of spectrophotometry in the diagnosis of melanoma

Antonio Daponte, Fabrizio Ayala, Marco Palla, 2010, BMC dermatology.

Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients

Andrea Dominijanni, Mariaelena Capone, Paolo A Ascierto, 2015, Journal of Translational Medicine.

The role of BRAF V600 mutation in melanoma

Alessandro Testori, Paolo A Ascierto, Giuseppe Palmieri, 2012, Journal of Translational Medicine.

The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014

Paolo A Ascierto, P. Ascierto, S. Pignata, 2014, Journal of Translational Medicine.

Combination therapy: the next opportunity and challenge of medicine

Paolo A Ascierto, Francesco M Marincola, F. Marincola, 2011, Journal of Translational Medicine.

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.

Wei Zhou, Dirk Schadendorf, Reinhard Dummer, 2015, The Lancet. Oncology.